FindTrial
Sign In

LIVE ATTENUATED

DRUG3 trials

Sponsors

Biothervax SpA, Vaestra Goetalandsregionen, Rigshospitalet

Conditions

000 CFU in adults over 60 years of age.Pediatric cancerPrevention of measlesThe present Phase 2 clinical study will evaluate the safety and immunogenicity of the immunogenic formulation cGMP rBCG-N-RSV of 100and rubella by vaccinationmumps

Phase 2

Randomized, double-blind, phase 2 clinical trial controlled with conventional Bacillus Calmette-Guérin (BCG) vaccine to evaluate the safety and immunogenicity of a recombinant BCG vaccine that expresses the respiratory syncytial virus (RSV) nucleoprotein (N) (rBCG-N-RSV) in adults over 60 years of age.
Not yet recruitingCTIS2023-509048-80-01
Biothervax SpA000 CFU in adults over 60 years of age., The present Phase 2 clinical study will evaluate the safety and immunogenicity of the immunogenic formulation cGMP rBCG-N-RSV of 100
Target: 200Updated: 2025-03-17

Phase 4

A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
RecruitingCTIS2024-511182-10-01
Vaestra GoetalandsregionenPediatric cancer
Start: 2025-05-22Target: 160Updated: 2024-09-27
Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up
Not yet recruitingCTIS2026-526160-21-00
Rigshospitaletand rubella by vaccination, mumps, Prevention of measles
Target: 1000Updated: 2026-06-08